We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Your Password has changed! Please login again
Cart
Outdated Browser Detected
Our website has detected that you are using an outdated browser that will prevent you from accessing certain features.
Please use one of the below recommended browsers to improve your browsing experience
4040 LyoTec® Lyophilization Stoppers: Forward Thinking Innovation Combines Demonstrated Design Success with Expertise in Testing and Raw Material Selection
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, has released its 4040 LyoTec® Westar® Select Ready-to-Sterilize (RS) and Ready-to-Use (RU) Lyophilization Stoppers, the first components of a portfolio of vial closures to be developed using West’s new state-of-the art elastomer formulation, 4040/40 gray. By combining the demonstrated success of an established design and significant levels of expertise in testing and raw material selection, we have achieved improvements and optimized benefits across the spectrum of packaging attributes required for performance, quality, and safety of the packaging and delivery of lyophilized drug products.
Combining a breadth of historic knowledge with forward thinking best practices.
Quality by Design
The Quality by Design (QbD) principles are part of a proven practice of “starting and ending” with the customer’s needs in mind. With almost 100 years of experience in the parenteral drug packaging and delivery industry, West is uniquely positioned to leverage that experience and develop new elastomer components to meet the current and future needs of our customers and the patients as regulations continue to evolve.
Using a QbD approach brings us a deep understanding of the materials used for our primary closure components. This helps us reduce risks that may be posed to drug product quality by the closure. For 4040 LyoTec, “beginning with the end in mind” meant that all packaging and delivery decisions were directly related to the drug product quality and user/patient needs. Patient needs were incorporated into the drug product requirements, which were then cascaded to help define the packaging and delivery needs, making sure to always be inclusive of the elastomer configuration.
We have plans to do a deeper dive into the QbD process in another blog later this year, so make sure to check back later or subscribe here so that you get it sent right to your inbox as soon as it’s published.
4040/40 Elastomer Formulation
Launched in 2021, the 4040 formulation was developed using not only QbD principles, but also a strong understanding of the increasing testing and quality demands and regulatory scrutiny for injectable drug packaging. This includes the formulation chemistry, extractable profile, and risk mitigation for raw materials. Intentional focus on formulation methodology and optimization of processing parameters means mitigation of risks from particulates, extractables, and coring and fragmentation. It also means more efficient drying following stopper processing. We also focused on creating contingencies to mitigate risk due to raw material supply changes.
Forward thinking Extractables and Leachables profiling
Informed by West’s considerable expertise in extractables and leachables testing, a forward-thinking approach was also taken to support our customers’ evaluation and use of the 4040 LyoTec stoppers. We first performed extensive material characterization studies to identify potential leachable substances using a wide range of drug solvent systems, and then also studied the leachables profile of 4040 LyoTec stoppers versus comparator stoppers in partnership with Lyophilization Technology, Inc. (LTI). This simulation study is ongoing and evaluates the stopper leachables over time observed in both a mannitol lyo cake as well as a sorbent.
Our findings so far support our goal to reduce extractables to the lowest possible levels when compared to legacy rubber formulations, ultimately providing our customers with both a high-quality product and the supporting data to meet regulatory requirements.
Using FluroTec® barrier film on the top surface to prevent sticking to the lyo shelves and B2-coating result in minimized clumping or sticking of stoppers in the feeder bowl and smooth tracking with continuous flow of stoppers along the rails. Previously only offered in 4432 and 4416 formulations, being able to offer this design in our new 4040 formulation presents our customers with an exciting new option. 4040 LyoTec stoppers have a single-vent design that effectively minimizes twinning, an event where two stoppers interlock with each other, and one that can cause costly backups on packaging line. They are offered in both ready-to-sterilize and ready-to-use options and available in both 13mm and 20mm sizes for additional convenience and flexibility.
Besides having a naturally low level of particulates resultant, the 4040/40 formulation also has benefits specific to lyo applications. Like many of our existing elastomers, it is compatibility with steam sterilization or gamma irradiation (< 45 kGy), providing helpful processing flexibility (see our TR 2021/238: 4040/40 Lyophilization Stoppers - Aging and Gamma Irradiation Study); it also been optimized for drying efficiency to improve steam sterilization throughput and boasts a residual moisture content for ready-to-use (steam sterilized) stoppers of ≤ 0.2% water, currently the lowest of any West lyophilization stoppers.
The bottom line
West’s new 4040 LyoTec stoppers use a state-of-the-art 4040 formulation developed with multi-dimensional elastomer expertise and a quality by design development approach. In doing so, we have achieved a broad range of improvements and optimized benefits required for manufacturing performance, functionality, quality and safety, enabling our customers to confidently deliver their drug product to patients in the safest and most effective way possible.
West’s products are sold on the basis that it is the customer’s responsibility to evaluate and test the West product to determine its compatibility with other materials and fitness for any end use. WEST MAKES NO WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR PARTICULAR PURPOSE, RELATING TO THE INFORMATION ABOVE.
LyoTec®, Westar®, and FluroTec® are trademarks and registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. FluroTec® and B2-coating technologies are licensed from Daikyo Seiko, Ltd.
Experimental characterization of an elastomer plunger in a particular pre-filled syringe system is essential to help pharmaceutical manufacturers determine whether that plunger is suitable for intended use. The strategy for a characterization study must consider relevant factors, in particular, compatibility with drug product and the ability to enable consistent delivery of drug product (dosage and time), by a clinician or by an autoinjector.
After welcoming new Taiwan colleagues from Exosite to West three months ago, we are excited to announce the grand opening of our Taipei office, which marks another Digital Technology Center (DTC) in the Asia Pacific region.
My name is Michele Polinsky and I am a breast cancer survivor.<br />These days it’s the simple things that make me happy. Watching my daughter play soccer at Virginia Tech, taking my son to high school and watching his soccer games. Celebrating holidays and birthdays. Simple things that you take for granted when you are healthy. And you start to worry won’t be in your future when you are first diagnosed with cancer. It’s a scary time.
Michele Polinsky
VP Global Communications and Corporate Philanthropy
The regulatory environment is moving to a more science-based approach to Container Closure Integrity (CCI). This is driven by the recent publication of United States Pharmacopeia Chapter <1207> Package Integrity Evaluation – Sterile Products. Recently, West gave a webinar (377 registrants) titled <a href="https://www.youtube.com/watch?v=5K8R1jumXyU&feature=youtu.be">Container Closure Integrity: Six Keys to Simplify Your Strategy and Execution</a>, that addressed Chapter <1207> and other topics. The survey questions (over 100 responses) from this webinar are instructive.
The Tech Group’s Vice President and General Manager, Mike Treadaway, was recently honored with the Spirit of Philanthropy Award at the Association of Fundraising Professionals Greater Arizona Chapter’s 30<sup>th</sup> Annual Philanthropy Leadership Awards Dinner. The celebration honors those who advance philanthropy with awards including the Spirit Award, which recognizes outstanding philanthropic contributions to nonprofit organizations.